Cargando…

PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models

Immunology-based interventions have been proposed as a promising curative chance to effectively attack postoperative minimal residual disease and distant metastatic localizations of prostate tumors. We developed a chimeric antigen receptor (CAR) construct targeting the human prostate-specific membra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuccolotto, Gaia, Fracasso, Giulio, Merlo, Anna, Montagner, Isabella Monia, Rondina, Maria, Bobisse, Sara, Figini, Mariangela, Cingarlini, Sara, Colombatti, Marco, Zanovello, Paola, Rosato, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184866/ https://www.ncbi.nlm.nih.gov/pubmed/25279468 http://dx.doi.org/10.1371/journal.pone.0109427

Ejemplares similares

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs
por: Montagner, Isabella Monia, et al.
Publicado: (2014)

Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2015)

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging
por: Frigerio, Barbara, et al.
Publicado: (2016)

In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe
por: Mazzocco, Claire, et al.
Publicado: (2016)

IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model
por: Wang, Dawei, et al.
Publicado: (2020)

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors
por: Turrini, Riccardo, et al.
Publicado: (2017)

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
por: Lütje, Susanne, et al.
Publicado: (2019)

Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review
por: Frigerio, Barbara, et al.
Publicado: (2021)

The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways(1)
por: Colombatti, Marco, et al.
Publicado: (2009)

Correction: The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways(1)
por: Colombatti, Marco, et al.
Publicado: (2009)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer
por: Turrini, Riccardo, et al.
Publicado: (2011)

Anti-PSMA (124)I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle
por: Frigerio, B., et al.
Publicado: (2019)

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
por: Minn, Il, et al.
Publicado: (2019)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

Impact of γ-chain cytokines on EBV-specific T cell cultures
por: Merlo, Anna, et al.
Publicado: (2010)

Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “in vitro” and correlating with progression “in vivo”
por: Perico, Maria Elisa, et al.
Publicado: (2016)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Development of (177)Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen
por: Carpanese, Debora, et al.
Publicado: (2020)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging
por: Hu, Kongzhen, et al.
Publicado: (2022)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

In vivo generated human CAR T cells eradicate tumor cells
por: Agarwal, Shiwani, et al.
Publicado: (2019)

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
por: Song, De-Gang, et al.
Publicado: (2016)

Mechanical Forces as Determinants of Disseminated Metastatic Cell Fate
por: Montagner, Marco, et al.
Publicado: (2020)

Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor
por: Schutsky, Keith, et al.
Publicado: (2015)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells
por: Ombrato, Luigi, et al.
Publicado: (2020)

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

Alpha-PET for Prostate Cancer: Preclinical investigation using (149)Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022)

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer
por: Murce, Erika, et al.
Publicado: (2023)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation
por: Patel, Priya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u87ii227gh6b5e100v8jual7ie